genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2014
Myelofibrosis
Cancer
Partial Clinical Hold in Myelofibrosis Trial Is Geron’s Latest Setback
Insights
Biopharma Blossoming in the Garden State
Cancer
Baxter, CTI Ink $172M+ Licensing Deal for Myelofibrosis Drug
Cancer
Sanofi Presents Encouraging Phase III Data for Myelofibrosis Drug
Cancer
EC Clears First Myelofibrosis Drug
Cancer
Cell Therapeutics Pays $30M in Cash and Stock for S*BIO’s Selective JAK2 Inhibitor
Industry News
Promedior Raises $21.5M to Progress Fibrotic Diseases Pipeline
Insights
M&A Activity Likely to Stay Hot in 2012 Though Blockbusters May Be Fewer
Cancer
Mundipharma Commits $50M to Infinity’s PI3K Inhibitor Program in 2013
Cancer
FDA Sanctions Incyte’s Jakafi for Treating Myelofibrosis
1
2
3
Page 2 of 3
Scroll Up
